Evidence map›Paper›PMID 26305864›Full record

ArticleBritish journal of cancer2015

Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.

Robert N Jorissen, Michael Christie, Dmitri Mouradov, Anuratha Sakthianandeswaren, Shan Li, Christopher Love, Zheng-Zhou Xu, Peter L Molloy, Ian T Jones, Stephen McLaughlin and 12 more

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Association ofGenetics research · 2022
    Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Intestinal Wnt in the transition from physiology to oncology.World journal of clinical oncology · 2022
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 2 countries.

Robert N JorissenSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Michael ChristieSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Dmitri MouradovSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Anuratha SakthianandeswarenSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Shan LiSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Christopher LoveSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Zheng-Zhou XuCSIRO Preventative Health Flagship, Animal, Food & Health Sciences Division, North Ryde, NSW 2113, Australia.
Peter L MolloyCSIRO Preventative Health Flagship, Animal, Food & Health Sciences Division, North Ryde, NSW 2113, Australia.
Ian T JonesDepartment of Colorectal Surgery, Royal Melbourne Hospital, Parkville, VIC 3050, Australia.
Stephen McLaughlinDepartment of Colorectal Surgery, Western Hospital, Footscray, VIC 3011, Australia.
Robyn L WardLowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, Sydney, NSW 2052, Australia.
Nicholas J HawkinsSchool of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
Andrew R RuszkiewiczDepartment of Surgical Pathology, SA Pathology, Adelaide, SA 5000, Australia.
James MooreDepartment of Colorectal Surgery, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
Antony W BurgessFaculty of Medicine, Dentistry and Health Sciences, Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.
Dana BusamJ. Craig Venter Institute Rockville, MD, 20850, USA.
Qi ZhaoLudwig Collaborative Laboratory for Cancer Biology and Therapy, Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Robert L StrausbergLudwig Collaborative Laboratory for Cancer Biology and Therapy, Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Lara LiptonSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Jayesh DesaiSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Peter GibbsSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Oliver M SieberSystems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Walter and Eliza Hall Institute of Medical Research · AUUniversity of Melbourne · AUCommonwealth Scientific and Industrial Research Organisation · AUJohns Hopkins University · USThe Royal Melbourne Hospital · AUUNSW Sydney · AUFootscray Hospital · AUJ. Craig Venter Institute · USRoyal Adelaide Hospital · AUSouth Australia Pathology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAPC mutations (APC-mt) occur in ∼70% of colorectal cancers (CRCs), but their relationship to prognosis is unclear.

methodsAPC prognostic value was evaluated in 746 stage I-IV CRC patients, stratifying for tumour location and microsatellite instability (MSI). Microarrays were used to identify a gene signature that could classify APC mutation status, and classifier ability to predict prognosis was examined in an independent cohort.

resultsWild-type APC microsatellite stable (APC-wt/MSS) tumours from the proximal colon showed poorer overall and recurrence-free survival (OS, RFS) than APC-mt/MSS proximal, APC-wt/MSS distal and APC-mt/MSS distal tumours (OS HR⩾1.79, P⩽0.015; RFS HR⩾1.88, P⩽0.026). APC was a stronger prognostic indicator than BRAF, KRAS, PIK3CA, TP53, CpG island methylator phenotype or chromosomal instability status (P⩽0.036). Microarray analysis similarly revealed poorer survival in MSS proximal cancers with an APC-wt-like signature (P=0.019). APC status did not affect outcomes in MSI tumours. In a validation on 206 patients with proximal colon cancer, APC-wt-like signature MSS cases showed poorer survival than APC-mt-like signature MSS or MSI cases (OS HR⩾2.50, P⩽0.010; RFS HR⩾2.14, P⩽0.025). Poor prognosis APC-wt/MSS proximal tumours exhibited features of the sessile serrated neoplasia pathway (P⩽0.016).

conclusionsAPC-wt status is a marker of poor prognosis in MSS proximal colon cancer.

Indexed as

Adenomatous Polyposis Coli ProteinAdultAgedClass I Phosphatidylinositol 3-KinasesColonic NeoplasmsCpG IslandsDisease-Free SurvivalFemaleGenes, p53Genes, rasHumansMaleMicrosatellite InstabilityMicrosatellite RepeatsMiddle AgedNeoplasm Recurrence, LocalAdenomatous Polyposis Coli ProteinAPC protein, humanBRAF protein, humanClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesPIK3CA protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID26305864
PMCPMC4578087
OpenAlexW2283224797

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.